CNS Pharmaceuticals (CNSP) Short-term Investments (2018 - 2019)
CNS Pharmaceuticals' (CNSP) quarterly Short-term Investments came in at $269399.0 in Q3 2019, down 1.1% on a QoQ basis from $272397.0 in Q4 2018.
CNS Pharmaceuticals (CNSP) Short-term Investments (2018 - 2019) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 2 years of Short-term Investments data on file, last reported at $269399.0 in Q3 2019.
- Quarterly Short-term Investments changed N/A year-over-year to $269399.0 in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $269399.0 (changed N/A YoY) and the FY2018 annual result came in at $272397.0, changed N/A from the prior year.
- Short-term Investments eased to $269399.0 in Q3 2019, from $272397.0 in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $272397.0 in Q4 2018 to a low of $269399.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CNS Pharmaceuticals | 2.65 Mn | -4.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 269,399.00 |
| Dec 31, 2018 | 272,397.00 |